5月21日,上海医药(601607/02607)发布公告,近日公司下属的上药禾丰的重酒石酸去甲肾上腺素注射液(规格:1ml:2mg)已通过国家药监局的仿制药一致性评价,并获得批准通知书。该药品主要用于急性低血压状态的血压控制,具备重要的临床应用价值。
公司为该药品1ml:2mg规格一致性评价累计投入研发费用约为160万元。根据IQVIA数据库,2024年中国大陆医院采购重酒石酸去甲肾上腺素注射液(1ml:2mg)的金额达到15.84亿元。通过一致性评价的药品在医保支付及医疗机构采购等领域将获得更大的支持,这将有助于上药禾丰扩大市场份额,提高市场竞争力。
2025年一季度,上海医药实现收入707.63亿元,归母净利润13.33亿元。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.